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Methods: We investigated whether chronic treatment with paroxetine, a selective serotonin reuptake
inhibitor, mitigates Ab pathology in plaque-bearing double-transgenic amyloid precursor protein
(APP)swe/presenilin 1 (PS1)DE9 mutants. In addition, we addressed whether serotonin depletion affects
Ab pathology. Treatments were assessed bymeasurement of serotonin transporter occupancy and high-
performance liquid chromatography. The effect of paroxetine on Ab pathology was evaluated by ste-
reological plaque load estimation and Ab42/Ab40 ratio by enzyme-linked immunosorbent assay.
Results: Contrary to our hypothesis, paroxetine therapy did not mitigate Ab pathology, and depletion
of brain serotonin did not exacerbate Ab pathology. However, chronic paroxetine therapy increased
mortality in APPswe/PS1DE9 transgenic mice.
Discussion: Our results question the ability of selective serotonin reuptake inhibitor therapy to
ameliorate established Ab pathology. The severe adverse effect of paroxetine may discourage its
use for disease-modifying purposes in Alzheimer’s disease.
 2018 Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords: Alzheimer’s disease; Cerebral amyloidosis; Neocortex; Monoamine; Serotonin; Selective serotonin reuptake in-hibitor; SERToccupancy; [3H]DASB; Autoradiography; Transgenicmouse model; 5,7-dihydroxytryptamine; Ste-
reology1. Introduction
The serotonergic system degenerates in Alzheimer’s dis-
ease (AD) along with the cholinergic and noradrenergic sys-
tems [1–3]. In patients with AD, the level of serotoninsts: No conflicts of interest for any of the authors.
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licenses/by-nc-nd/4.0/).(5-hydroxytryptamine [5-HT]) is significantly reduced in
several cortical regions, in particular in the frontal and tempo-
ral cortex [4,5]. This pathological change has been suggested
to contribute to the depressive symptoms that frequently
precede the cognitive decline in patients with AD [6–8]. It
is still being disputed whether antidepressive treatment of
patients with AD with selective serotonin reuptake
inhibitors (SSRIs) impacts on the decline of cognition in
AD [9–12] or the conversion from mild cognitive
impairment to AD [13]. In AD, the density of specific corticalation. This is an open access article under the CC BY-NC-ND license (http://
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thology and negatively to cognitive performance [14], with
a reduced density of the 5-HT4R and 5-HT6R being observed
in mild cognitive impairment [15–17]. Evidence that SSRI
treatment impacts on Ab accumulation comes from positron
emission tomography studies, showing reduced uptake of
Pittsburgh compound B, a proposed marker of Ab
pathology, in the brains of individuals with a history of
SSRI therapy, including citalopram and fluoxetine [18]. In
addition, acute, successive administration of citalopram
(30 mg) to healthy individuals with 2 hours interval is re-
ported to diminish cerebrospinal fluid levels of Ab [19].
Interestingly, studies in transgenic mouse models of AD
have suggested that SSRI treatment has major impact on
Ab pathology [18–20]. In the APPswe/PS1DE9 (amyloid
precursor protein [APP]/presenilin 1 [PS1]) transgenic
mouse, which is a well-established model of Ab pathology
[21], 4 months treatment with citalopram (8 mg/kg/day per
os) from 3 months of age results in w50% lower Ab plaque
load in the neocortex at 7 months of age [18]. In 6-month-old
APP/PS1 mice, 4 weeks of treatment with citalopram (10 mg/
kg/day i.p.) impairs initial Ab plaque formation and growth
[18]. Five months treatment with paroxetine (5 mg/kg/day
i.p.) from 5 months of age results in lower Ab levels at 10
months of age in the hippocampus of 3 ! Triple-Tg mice
[20], a model of combined Ab and tau pathology. In addition,
5-week treatment with fluoxetine (10 mg/kg/day i.p.) is sug-
gested to reduce Ab load in 18-month-old APP/PS1 mice
[22], at an age when these mice show a reduction in 5-HT
in the neocortex [23,24]. Finally, infusion of 5-HT into the
hippocampus of APP/PS1 mice has been reported to reduce
interstitial levels of Ab [18], by mechanisms involving stim-
ulation of the 5-HT4R and 5-HT6R and increased processing
of APP via the nonamyloidogenic route [25,26].
Importantly, there are still no preclinical studies, where
plaque-bearing APP/PS1 mice have been chronically treated
with doses of SSRI, resulting in z80% occupancy of the
serotonin transporter (SERT), which is considered
therapeutic for the treatment of depression [27]. Therefore,Table 1
Study design
Experimental group Treatment/intervention
Genotype
Wt (n) APP/P
Nine months paroxetine treatment Vehicle 20 14
Paroxetine 10 mg/kg/day 15 5
Vehicle 15 7
Paroxetine 5 mg/kg/day 11 7
Three months paroxetine treatment Vehicle 6 10
Paroxetine 10 mg/kg/day 6 7
Three months 5,7-DHT-induced
loss of 5-HT
Sham 6 6
5,7-DHT 6 6
Abbreviations: 5,7-DHT, 5,7-dihydroxytryptophan; APP, amyloid precursor pro
*Results reported in Olesen et al. [29].
yResults reported in Olesen et al. [30].
zUnpublished results.we tested the hypothesis that chronic treatment of plaque-
bearing 9-month-old APP/PS1 mice for 9 months with parox-
etine (5 or 10mg/kg/day peros) wouldmitigate Ab pathology
and improve behavior (locomotion, social memory). We also
tested the hypothesis that a neurotoxin-induced loss of
cortical 5-HTat 9 months of age would impact on Ab pathol-
ogy at 12 months. The results of this study question the pro-
posed beneficial effect of SSRI therapy and 5-HT on Ab
pathology in mice with manifest Ab pathology.2. Methods
2.1. Paroxetine treatment and neurotoxin injection
Paroxetine: APPswe/PS1DE9 (APP/PS1) and littermate
wild-type (Wt) mice [21] were bred on a B6C3 background
in house or at Taconic A/S, Denmark [28]. Paroxetine (Se-
roxat oral solution 2 mg/mL, GSKline) was administered
in the drinking water in a dose of 10 mg/kg/day or 5 mg/
kg/day (Table 1) to 9-month-old male APP/PS1 and Wt
mice. APP/PS1 and Wt controls received normal drinking
water. Treatment efficacy was assessed by autoradiographic
measurement of the SERT occupancy using [3H]3-amino-4-
(2-dimethylaminomethylphenylsulfanyl)-benzonitrile, as de-
tailed in Supplementary Methods.
Neurotoxin: To destroy 5-HT fibers and neurons,
5,7-dihydroxytryptophan (5,7-DHT) was stereotaxically in-
jected into the lateral ventricles of 9-month-old male APP/
PS1 and Wt mice (Table 1), as described elsewhere [31],
but injecting a total dose of 80 mg 5,7-DHT. Mice with unsuc-
cessful lesions, as determined by the measurement of 5-HT in
neocortical tissues, were excluded from statistical analysis
(Danish Veterinary & Food Administration: J.no. 2007/562-
50, J.no. 2012-15-2935-00,023, J.no. 2012-DY-2934-00,008).
Tissue processing: See Supplementary Methods.
2.2. Behavior
The behavior of 18-month-old mice was assessed using
the open field, the elevated plus maze, and the socialTreatment period
(months) Behavioral analysisS1 (n)
9–18 months Open field, elevated plus maze, social
interaction, social memory* Y-mazey
9–18 months Open field, elevated plus maze, social
interaction, social memory Y-mazez
9–12 months Not done
9–12 months Open field, social interaction, social memory
Y-mazez
tein; 5-HT, 5-hydroxytryptamine; PS1, presenilin 1.
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sessed using the open field test [32]. All tests were per-
formed in the light phase of 24-hr light/dark cycle. For
details, see Supplementary Methods.2.3. High-performance liquid chromatography for 5-HT
Monoamine levels were assessed in perchlorate extracts
of the dissected tissues using high-performance liquid chro-
matography with electrochemical detection [24,32]. The
detection limit for 5-HTwas 30 fmol on column. The detec-
tion level in tissues was 0.25 pmol/mg wet weight.2.4. Immunohistochemistry for human Ab
Cryostat and vibratome sections were demasked free
floating in 70% formic acid diluted in H2O for 15 min at
room temperature, followed by staining for human Ab using
biotinylated monoclonal mouse-anti-Ab immunoglobulin G1
(6E10, Biosite), which was detected by horse radish
peroxidase-Streptavidin and developed with diaminobenzi-
dine. Sections were mounted on glass-slides, dehydrated,
and coverslipped from xylene in Depex. Paraffin sections
were demasked in Tris-ethylenediaminetetraacetic acid-
glucose-Buffer at 480 Watts for 15 min and stained as
mentioned previously. The protocol for SERT is given in
Supplementary Methods.2.5. Enzyme-linked immunosorbent assay for human Ab
Samples were processed according to the manufacturers
protocol (Invitrogen), whereafter the Ab was measured us-
ing Invitrogen Ab42 Human enzyme-linked immunosorbent
assay Kit (KHB3441) and Ab40 Human enzyme-linked
immunosorbent assay Kit (KHB3482), as described in
Supplementary Materials. Data expressed in pg/mg protein
were used for calculation of the Ab42/Ab40 ratio.Fig. 1. 5-HT levels (pmol/mg wet weight) are reduced in frontal cortex of
old APP/PS1 mice. HPLC measurement of 5-HT in the frontal cortex of
18-month-old male APP/PS1 Tg and Wt mice. Data are expressed as
mean 6 SEM. Student t test; Tg, n 5 6; Wt, n 5 5. **P , .01. Abbrevia-
tions: 5-HT, 5-hydroxytryptamine; APP, amyloid precursor protein;
HPLC, high-performance liquid chromatography; SEM, standard error of
the mean; PS1, presenilin 1; ww, wet weight of dissected brain tissue.2.6. Quantification of Ab plaque load
The Ab plaque load was estimated in the neocortex by
the use of stereological grid counting, using the new
CAST software (Visiopharm), by an observer who was
blinded to the treatment of the mice. The estimation was
performed in 6.2 1/2 1.5 (mean 1/2 standard deviation)
sections per mouse in the 18-month-old APP/PS1 mice. For
details, see Supplementary Methods. The percentage of
neocortex covered by plaques in individual sections was
calculated as: Ab plaque load (%) 5 No. of Ab1 plaques
touching a cross (in a grid)/No. of crosses in neocortex !
100%. Plaque density was given by the number of plaques
per area, and plaque size by the number of crosses hitting
individual plaques. Data on Ab plaque load are presented
in dot diagrams, and plaque density and plaque size in
bar graphs. The coefficient of error (CE) of the estimate
of individual mice was used to calculate a mean CE forthe group. The CE values and the coefficient of variation
were calculated as done previously [33].2.7. Statistical methods
Data sets were tested for normality of distribution.
Bartlett’s test was used to check the equality of variances.
Binary logistic regression was used to assess the effects of
genotype, age, and treatment on mouse survival. Statistically
significant differences between groups were evaluated using
unpaired, two-tailed Student t tests, one-way analysis of
variance (ANOVA), or repeated measures two-way ANOVA,
followed by least significant difference post hoc tests. Ana-
lyses were performed using GraphPad software (Prism 4.0b)
forMacintosh or XLSTAT (version 2010.3.06) forWindows.
In one data set, one outlier .2 SDs from the mean was
excluded. Statistical difference is indicated as *P , .05,
**P , .01, ***P , .001, and ****P , .0001.3. Results
3.1. 5-HT is reduced in aging APP/PS1 mice
The 18-month-old male APP/PS1 mice showed a reduc-
tion in 5-HT levels of z40% in frontal cortex compared
with littermate Wt mice (P , .01, Student t test) (Fig. 1).
This reduction is within the range previously reported for
this AD model [23] and in line with the reduction in 5-HT
levels observed in frontal cortex of AD patients [5,6].3.2. Chronic paroxetine treatment reduces the survival of
APP/PS1 mice
Individually caged 9-month-old male APP/PS1 and Wt
micewere treated peroswith paroxetine (Seroxat oral solution
2 mg/mL, GSKline) for up to 9 months, whereas vehicle-
Fig. 2. Peroral paroxetine treatment reduces the survival of aging APP/PS1
mice. The survival was recorded for mice treated with paroxetine (prx) or
vehicle (veh) for 9 months and shown in a Kaplan-Meier diagram. The
APP/PS1 mice treated with paroxetine had a lower survival than all other
groups after 9 months of treatment. Numbers of mice before and after treat-
ment are shown, with the number before initiation of treatment indicated in
brackets. Abbreviations: APP, amyloid precursor protein; PS1, presenilin 1.
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etine treatment at 10 mg/kg/day per os reduced the survival of
APP/PS1mice (Fig. 2). Binary logistic regression showed that
the effect of treatment, genotype, and age on premature death
was statistically significant (c2 [3] 5 166.2, P , .001). The
model explained 27.8% of the variance in premature deaths
(Nagelkerke R2), and correctly classified 88.3% of cases.
The independent factors treatment (Wald score 5 39.3;
P , .001), genotype (Wald score5 46.6; P , .001), and age
(Wald score5 41.2;P,.001) added significantly to themodel
and increased the likelihood of death by 4.8, 5.6, and 1.3,
respectively. Because of the reduced survival rate, the dose
of paroxetine was reduced to 5 mg/kg/day (Table 1), resulting
in paroxetine serum levels of 40–50 nmol/L. Binary logistic
regressionof the effects of genotype, age, and5mg/kg/daypar-
oxetine treatment was significant (c2 [3] 5 56.7, P , .001),
with the independent factors age (Wald score 5 41.2;
P , .001) and paroxetine (Wald score 5 5.3, P , .05), butFig. 3. Assessment of SERT occupancy by [3H]DASB radioligand binding. (A) A
brain sections fromWt mice administered paroxetine in the drinking water (5 mg/k
shown at the bottom. (B) Graphic presentation showing that the SERToccupancy (%
Data are expressed as mean 6 SEM. n 5 4/group. Abbreviations: [3H]DASB, [
standard error of the mean.not genotype (Wald score5 0.0;P..05), adding significantly
to themodel. Age and paroxetine treatment at 5mg/kg/day per
os increased the likelihood of premature death by 2.0 and 0.2,
respectively.
3.3. Clinically relevant occupancy is achieved by oral
paroxetine treatment
To ensure that all mice, including those treated with 5 mg/
kg/day per os, were treated with a clinically relevant dose of
paroxetine, we assessed the SERT occupancy in 18-month-
old Wt mice treated with paroxetine in a dose of 5 mg/kg/
day for 3 months. Vehicle-treated mice showed a high spe-
cific [3H]3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-
benzonitrile binding in all brain regions analyzed, except the
cerebellum (data not shown). In neocortex, the occupancy of
SERT in paroxetine-treated mice was 86% (Fig. 3). These re-
sults confirmed that the APP/PS1 and Wt mice were treated
with paroxetine doses considered therapeutic in humans [27].
3.4. Long-term paroxetine treatment has no effect on
established Ab pathology
The effect of the 9-month oral SSRI treatment was exam-
ined by comparing the Ab plaque load in 18-month-old par-
oxetine- and vehicle-treated APP/PS1 mice. The Ab plaque
load was estimated by the use of a stereological point count-
ing technique. The plaque load in the neocortex showed to be
comparable in paroxetine- and vehicle-treated mice (Student
t test: Veh, 18.06 0.7% (mean6 standard error of the mean)
vs. Prx, 16.56 1.2 %, P5 .27) (Fig. 4A and 4B). The mean
CE and coefficient of variation of the estimated plaque loads
are shown in Table 2. In addition, no difference was noted in
plaque density (P 5 .66, Student t test), and plaque size
(P . .05, all comparisons, Student t test), between vehicle-
and paroxetine-treated mice (Fig. 4C and 4D). The majority
of the plaques (.99%) were smaller than 7.0 ! 103 mm2, a
few ranged from 7.0–13.9! 103 mm2 (0.5%), and almost no
plaques were larger than 14.0 ! 103 mm2 (Fig. 4D).utoradiograms showing the binding of the [3H]DASB radioligand in sagittal
g/day) or vehicle from 15 to 18 months of age. Nonspecific binding (NSB) is
) of the paroxetine-treatedWt mice (5 mg/kg/day) is 86% in the neocortex.
3H]3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile; SEM,
Fig. 4. No effect on Ab pathology in 18-month-old APP/PS1 mice treated with paroxetine for 9 months. (A) Immunohistochemistry of coronal section for the
humanAb using the 6E10 antibody suggesting that the distribution and density of plaques is comparable in the neocortex of 18-month-old APP/PS1mice treated
with vehicle or paroxetine for 9 months. Bar: 200 mm. (B) Dot-diagram showing the % Ab plaque load in APP/PS1 mice treated with vehicle or paroxetine for 9
months. The horizontal line indicates the mean and the error bars, the SEM. Statistical comparison shows no difference in % Ab plaque load between groups
(Student t test,P5 .27). (C) Bar diagram showing the density of plaques in APP/PS1 treated with paroxetine (n5 12) or vehicle (n5 18). Student t test; P5 .66.
(D) Bar diagram showing the size distribution in % of plaques counted in APP/PS1 mice treated with paroxetine (n 5 12) or vehicle (n 5 18). Student t test;
P, .05, all comparisons. Abbreviations: Ab, amyloid-b; APP, amyloid precursor protein; NCx, neocortex; SEM, standard error of the mean; Str, Striatum; Veh,
vehicle; Prx, paroxetine; PS1, presenilin 1.
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load compared with baseline at the time when the paroxetine
treatment was initiated, groups of 3- and 9-month-old male
APP/PS1 mice were processed in parallel with the 18-
month-old APP/PS1 and Wt mice. As previously shown
for female APP/PS1 mice [28], the plaque load in the male
APP/PS1 mice increased steadily from 3 months
(0.04 6 0.04%) through 9 months (8.1 6 0.7%), to 18
months of age (19.8 6 0.9%) [One-way ANOVA:
F(2,28) 5 110.1, P , .0001]. The plaque load in the
paroxetine-treated 18-month-old APP/PS1micewas thereby
statistically higher than that in 9-month-old APP/PS1 mice
(Student t test 16.5 6 1.2% vs. 8.1 6 0.7%, P , .0001).Table 2
Precision of stereological estimates of the % Ab plaque load in paroxetine-
and vehicle-treated 18-month-old APP/PS1 transgenics
Treatment n
% Ab plaque load
Mean 6 SEM CE CV
Vehicle 18 18.0 6 0.7 0.07 0.17
Paroxetine 12 16.5 6 1.2 0.06 0.24
Abbreviations: SEM, standard error of the mean; Ab, amyloid-b; CE, co-
efficient of error; CV, coefficient of variation; APP, amyloid precursor pro-
tein; PS1, presenilin 1.
NOTE. The CE and CV are calculated as in West et al. [29].In conclusion, 9-month oral paroxetine treatment (10 and
5 mg/kg/day) does not mitigate Ab pathology in the
neocortex of 18-month-old male APP/PS1 mice.3.5. Paroxetine treatment impacts mouse behavior in both
APP/PS1 and Wt mice
Effects of paroxetine treatment (5 mg/kg/day) were evalu-
ated using the open field test, the elevated plus maze test, and
the social interaction test. Repeated measures two-way AN-
OVA showed no significant effect of genotype in the open
field (F[1,33] 5 0.76, P . .05), no genotype by treatment
interaction (F[1,33]5 0.18, P. .05), and only a tendency to-
ward an effect of the paroxetine treatment (F[1,33] 5 3.22,
P5 .08). Still, there was a significant effect of the paroxetine
treatment that reduced locomotion given by the number of
horizontal entries in both Wt and APP/PS1 mice (data not
shown) (F[5,165]5 2.86, P5 .02). No significant differences
were observed in any parameters in the elevated plus maze.
There was an effect of treatment on social interaction (two-
way ANOVA: F[1,31] 5 4.70, P 5 .04). However, compari-
son with vehicle- and paroxetine-treated mice showed no ef-
fect of treatment on individual behaviors, such as total contact
time, and latency. There was no effect of genotype on any pa-
rameters, and no significant effect was observed in the social
memory test (data not shown).
Fig. 5. No effect on Ab pathology in neocortex of 12-month-old APP/PS1 mice treated with paroxetine or subjected to a 5,7-DHT-induced depletion of 5-HT.
(A, B) Dot diagram showing the %Ab plaque load in the neocortex of 6E10-stained sections of the left hemisphere (A), and bar diagram showing the Ab42/Ab40
ratio in the right neocortex (B) of the same vehicle- and paroxetine-treated, 12-month-old APP/PS1 mice (Veh: n5 9 (one outlier. 2 standard deviations from
the mean was excluded), Prx: n5 6 (one sample not included in the ELISA for Ab40), Student t test, P5 .95). (C, D) Dot diagram showing the %Ab plaque load
in 6E10-stained sections of the left hemisphere (C), and bar diagram showing the Ab42/Ab40 ratio in the right neocortex (D) of the same 5,7-DHT- and sham-
injected 12-month-old APP/PS1 mice. (Student t test, n 5 6/group, P 5 .67). Horizontal lines and bar height indicate the means and the error bars, the SEM.
Abbreviations: Ab, amyloid-b; 5,7-DHT, 5,7-dihydroxytryptophan; APP, amyloid precursor protein; ELISA, enzyme-linked immunosorbent assay; Veh,
vehicle; Prx, paroxetine; PS1, presenilin 1; 5-HT, 5-hydroxytryptamine; SEM, standard error of the mean.
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pathology
In contrast to the studies by Cirrito et al. [18] and Nelson
et al. [20] in which mice were treated with SSRI for 4 to 5
months and brains were processed for Ab pathology at a
younger age, we treated mice with paroxetine (10 mg/kg/
day per os) or vehicle for 3 months and analyzed Ab pathol-
ogy in 12-month-old male APP/PS1 mice (Table 1) by quan-
tifying plaque load in the right neocortex, and by enzyme-
linked immunosorbent assay for Ab42 and Ab40 in the left
neocortex (Fig. 5A and 5B). There was no difference in pla-
que load between the paroxetine- and vehicle-treated APP/
PS1 mice (P . .05, Student t test) (Fig. 5A). In addition,
levels of Ab42 and Ab40 were unaffected by the treatment
(P . .05, Student t test) (data not shown) as was the ratio
of Ab42/Ab40 (P . .05, Student t test) (Fig. 5B), a risk
parameter for AD [34].3.7. Chronic loss of 5-HT has no effect on Ab pathology or
mouse behavior
We finally examined whether 5,7-DHT-induced seroto-
nergic deafferentation of the forebrain of 9-month-old
male APP/PS1 mice might impact Ab pathology at 12
months of age (Table 1). The serotonergic deafferentation
was validated by demonstration of undetectable levels of
5-HT and loss of SERT-immunopositive fibers in the
neocortex (data not shown). The plaque load was compara-
ble in sham-injected and deafferented APP/PS1 mice
(2.4 6 0.9% vs. 2.7 6 0.6%, P 5 .29, Student t test)
(Fig. 5C). Similarly, the levels of soluble Ab42 and Ab40 in
the neocortex from the same mice were unaffected by the
treatment (data not shown, P . .05, Student t test), as was
the ratio of Ab42/Ab40 (P . .05, Student t test) (Fig. 5D).
The behavioral testing at baseline in the open field test
showed higher locomotor activity of APP/PS1 compared
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n 5 16). However, no significant differences were observed
in the open field and social interaction tests between sham-
injected and deafferented APP/PS1 mice at 12 months
(data not shown, Sham: n 5 6; 5,7-DHT: n 5 6). These re-
sults suggest that 3-month impairment of 5-HT signaling has
no effect on neither Ab pathology nor behavior of 12-month-
old APP/PS1 mice.4. Discussion
4.1. Main findings
The main results of this study showed that chronic per os
treatment with paroxetine of plaque-bearing 9-month-old
APP/PS1 mice for up till 9 months was unable to mitigate
Ab pathology. However, treatment with paroxetine
increased mortality for transgenic mice exclusively and
reduced locomotion in both transgenic and littermate control
mice. In addition, neurotoxin-induced serotonergic deaffer-
entation of 9-month-old APP/PS1 mice had no impact on
Ab pathology in 12-month-old male APP/PS1 mice. These
results were unexpected as previous studies have suggested
that SSRIs mitigate Ab pathology [18–20,22]. Considering
the therapeutic implications of the potential option to
impact directly on Ab pathology in individuals developing
AD, it is important to understand the background for these
apparently contradictory results.
4.2. What is already known
Previous studies have reported reduced Ab pathology af-
ter shorter periods of SSRI treatment in younger APP/PS1
and 3 ! TgAD mice [18–20]. In Cirrito et al. [18], citalo-
pram treatment of APP/PS1 mice from 3 to 7 months of
age, resulted in a lower plaque load in neocortex of APP/
PS1 mice. In the study by Sheline et al. [19], 4 weeks of cit-
alopram treatment of 6-month-old APP/PS1 mice impaired
the formation and growth of cortical plaques at 7 months
[18]. Another study using 17-month-old APP/PS1 mice sug-
gested that 5-week treatment with fluoxetine (10 mg/kg/day
i.p.) was sufficient to mitigate plaque load; however, as
acknowledged by the authors, the plaque load was not quan-
tified [22]. In contrast, a study from our own group showed
no or minor effect on the Ab levels in neocortex and hippo-
campus in APP/PS1 mice treated from 3 to 9 months of age
with escitalopram in a dose of 5 mg/kg/day per os, leading to
z80% occupancy of SERT [31]. This suggests that the dif-
ferences in results cannot simply be explained by differences
in the time of treatment start, but that other factors, such as
sex, genetic background, and type of SSRI should be taken
into consideration. Studies suggest that the R-enantiomer
present in citalopram but not in escitalopram may reduce
levels of Ab by SERT-independent mechanisms, possibly
by increasing the g-secretase activity, increasing the nona-
myloidogenic processing of APP, and reducing the produc-
tion of Ab [35,36].4.3. Strengths and limitations
The fact that the APP/PS1 and Wt mice were all litter-
mates, of the same sex, and housed identically during their
entire life span affords credibility to our findings of (1) a
lack of effect of chronic paroxetine treatment on estab-
lished Ab pathology and (2) premature death by paroxetine
treatment in APP/PS1 mice. APP/PS1 mice are known to
exhibit seizure activity [37,38], which also occurs
frequently in patients with AD [39]. Recently, fluoxetine
administered in a dose of 15 mg/kg/day i.p. for 55 days
to 19-week-old male APP/PS1 mice was found to increase
seizure activity and mortality [40]. Although, the lowest
paroxetine dose used in our study was 5 mg/kg/day, which
is higher than the 0.3 mg/kg/day considered therapeutic in
humans [27], it would be important to know if paroxetine
in a dose of 0.3 mg/kg/day and therapeutic concentrations
of e.g. citalopram increase seizure activity and mortality of
AD transgenic mice. Importantly, we did not observe any
mortality in the APP/PS1 mice treated with escitalopram
(5 mg/kg/day per os) from 3 to 9 months of age [31]. It
is also possible that chronic SSRI treatment, especially
when administered i.p., may enhance stress and reduce sur-
vival in APP/PS1 mice. Under stressful conditions, SSRI
treatment exaggerates, rather than ameliorates depressive-
like symptoms in C57BL/6 mice [41]. In the present study,
APP/PS1 and littermate Wt mice were treated with a clin-
ically relevant paroxetine dose starting at an age when Ab
pathology is well established, but still increasing [28],
similar to the progression of Ab pathology in patients
with AD [42]. Despite these similarities, the present results
have been obtained in a mouse model and cannot be
directly extrapolated to AD, which is a complex, polygenic
neurodegenerative disease. Finally, it is increasingly recog-
nized that Ab pathology and associated molecular path-
ways represent only one out of several pathogenic
mechanisms in AD, including tau pathology [43,44],
brain inflammation [45], and cholinergic deficits [46],
that can be modulated by serotonergic signaling in AD
[47,48].
4.4. What does this study add and how to move forward?
In contrast to previous short-term studies using the same
mouse model, this extended study demonstrated that
chronic, long-term treatment with paroxetine did not
ameliorate already established Ab pathology in old APP/
PS1 transgenic mice and selectively increased mortality
in the APP/PS1 transgenic mice, but not in controls. Future
studies, examining the effect of chronic treatment with
newer generation SSRIs in APP/PS1 and tau transgenic
mice, should be performed to determine whether the
observed lack of beneficial effects and the serious adverse
effect is specific for paroxetine. Knowing the answer to
these questions is important for adjusting or reconsidering
the wide-spread use of SSRIs in individuals with mild
cognitive impairment and AD.
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1. Systematic review: Chronic treatment with selective
serotonin reuptake inhibitors (SSRIs) has been sug-
gested to mitigate amyloid-b (Ab) pathology in
mouse models of Alzheimer’s disease and in patients
with Alzheimer’s disease, in addition to having an
antidepressant mechanism of action.
2. Interpretation: We tested the hypothesis that chronic
treatment with paroxetine, a selective serotonin reup-
take inhibitor, would mitigate Ab pathology in
plaque-bearing double-transgenic APPswe/PS1DE9
mutants. In addition, we addressed whether serotonin
depletion influences Ab pathology. Contrary to our
hypothesis, chronic, long-term therapy with paroxe-
tine did not mitigate Ab pathology. However, the
therapy increased mortality for transgenic mice
exclusively. Depletion of serotonin did not exacer-
bate Ab pathology.
3. Future directions: Future studies, examining the ef-
fect of chronic treatmentwith newer generation selec-
tive serotonin reuptake inhibitors in APP/PS1 and tau
transgenics, should be performed to determine
whether the observed lack of beneficial effects and
the serious adverse effect are specific for paroxetine.References
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